Innovation1 Biotech Inc. (IVBT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Innovation1 Biotech Inc. (IVBT) trades at $0.00 with AI Score 47/100 (Weak). Innovation1 Biotech Inc. Market cap: 5K, Sector: Financial services.
Last analyzed: Mar 15, 2026Innovation1 Biotech Inc. (IVBT) Financial Services Profile
Innovation1 Biotech Inc. operates within the financial services sector as a shell company focused on pharmaceutical product development and sales. The company markets natural supplements under the NutraFlu and Nutravid19 brands, targeting flu and long covid symptoms, while also advancing NLC001, a drug in Phase II clinical trials, indicating a blend of current revenue generation and future potential.
Investment Thesis
Innovation1 Biotech Inc. presents a speculative investment opportunity given its focus on developing treatments for long covid and other viral indications. The company's NLC001 drug, currently in Phase II clinical trials, represents a potential value driver if proven effective and approved for market use. The company's existing revenue stream from NutraFlu and Nutravid19 supplements could provide financial stability while the drug development progresses. However, the company's high beta of 17.37 indicates significant volatility, reflecting the inherent risks associated with pharmaceutical development and the shell company structure. Investors should carefully consider the risks associated with clinical trial outcomes, regulatory approvals, and market acceptance of new treatments. The company's success hinges on the successful development and commercialization of NLC001, making it a high-risk, high-reward investment.
Based on FMP financials and quantitative analysis
Key Highlights
- Focus on developing NLC001, a drug in Phase II clinical trials for long covid and other viral indications.
- Markets natural supplements under the NutraFlu and Nutravid19 brands for flu and long covid symptom relief.
- Operates with a beta of 17.37, indicating high volatility compared to the market.
- The company is based in New York, New York.
- No dividend yield, suggesting reinvestment of earnings into research and development.
Strengths
- Focus on emerging health needs (long covid).
- Proprietary drug in Phase II clinical trials.
- Existing revenue stream from supplement sales.
Weaknesses
- High beta indicating significant volatility.
- Reliance on successful drug development.
- Limited financial resources compared to larger pharmaceutical companies.
Catalysts
- Upcoming: Results from Phase II clinical trials for NLC001 (within 12-18 months).
- Ongoing: Expansion of NutraFlu and Nutravid19 product lines.
- Ongoing: Potential partnerships with larger pharmaceutical companies (within 24 months).
Risks
- Potential: Failure of NLC001 in clinical trials.
- Potential: Regulatory hurdles for drug approval.
- Ongoing: High beta indicating significant volatility.
- Ongoing: Limited financial resources compared to larger pharmaceutical companies.
- Potential: Competition from established pharmaceutical companies.
Growth Opportunities
- Successful completion of Phase II clinical trials for NLC001: Positive results from the Phase II clinical trials could significantly increase the company's valuation. The long covid treatment market is projected to grow as the prevalence of the condition increases, creating a substantial market opportunity for effective treatments. Timeline: Anticipated results from Phase II trials within the next 12-18 months.
- Expansion of the NutraFlu and Nutravid19 product lines: Expanding the range of supplements targeting flu and long covid symptoms could drive revenue growth. The market for natural supplements is growing, driven by increasing consumer interest in preventative health measures. Timeline: Ongoing product development and marketing efforts.
- Partnerships with larger pharmaceutical companies: Collaborating with established pharmaceutical companies could provide access to funding, expertise, and distribution channels. Strategic partnerships can accelerate the development and commercialization of NLC001 and other products. Timeline: Potential partnerships within the next 24 months.
- Acquisition of complementary technologies or companies: Acquiring companies with complementary technologies or products could expand Innovation1 Biotech Inc.'s capabilities and market reach. Acquisitions can provide access to new markets and technologies, accelerating growth. Timeline: Potential acquisitions within the next 36 months.
- Geographic expansion of product sales: Expanding the geographic reach of NutraFlu and Nutravid19 sales could drive revenue growth. The global market for supplements is growing, creating opportunities for international expansion. Timeline: Potential expansion into new markets within the next 24-36 months.
Opportunities
- Growing market for long covid treatments.
- Increasing demand for natural supplements.
- Potential partnerships with larger pharmaceutical companies.
Threats
- Failure of NLC001 in clinical trials.
- Regulatory hurdles for drug approval.
- Competition from established pharmaceutical companies.
Competitive Advantages
- Proprietary formulations for NutraFlu and Nutravid19 supplements.
- Intellectual property rights for NLC001 drug.
- First-mover advantage in the long covid treatment market (if NLC001 is approved).
About IVBT
Innovation1 Biotech Inc., based in New York, is a financial services company operating as a shell company within the pharmaceutical industry. The company is involved in researching, developing, producing, and selling pharmaceutical products and supplements. Its product line includes natural supplements marketed under the NutraFlu and Nutravid19 brands, designed to alleviate symptoms associated with the flu and long covid. Additionally, the company offers other supplement and medical nutrition products. A key aspect of Innovation1 Biotech Inc.'s operations is the development of NLC001, a drug currently in Phase II clinical trials. This drug is being investigated for its potential to treat long covid and other viral indications. The company's focus on both immediate consumer health needs through supplements and long-term pharmaceutical solutions positions it uniquely within the market. Innovation1 Biotech Inc.'s business model combines revenue generation from existing supplement sales with the potential for future growth through the successful development and commercialization of NLC001. This dual approach allows the company to address current market demands while simultaneously investing in innovative treatments for emerging health challenges.
What They Do
- Researches and develops pharmaceutical products.
- Produces and sells natural supplements.
- Offers supplements for the treatment of flu symptoms.
- Offers supplements for the treatment of long covid symptoms.
- Develops NLC001, a drug in Phase II clinical trials.
- Targets viral indications with its pharmaceutical products.
Business Model
- Generates revenue through the sale of NutraFlu and Nutravid19 supplements.
- Focuses on developing and commercializing pharmaceutical products.
- Seeks to monetize its research and development efforts through drug sales.
Industry Context
Innovation1 Biotech Inc. operates within the shell companies industry, a segment of the financial services sector characterized by companies often formed for specific purposes, such as mergers, acquisitions, or raising capital. The pharmaceutical industry, where Innovation1 Biotech Inc. develops its products, is highly competitive and research-intensive, with significant regulatory oversight. Market trends include a growing demand for treatments for viral infections and related conditions like long covid, creating opportunities for companies developing innovative therapies. The competitive landscape includes both established pharmaceutical giants and smaller biotech firms, all vying for market share in the treatment of infectious diseases.
Key Customers
- Individuals seeking relief from flu symptoms.
- Individuals seeking relief from long covid symptoms.
- Consumers of natural supplements and medical nutrition products.
Financials
Chart & Info
Innovation1 Biotech Inc. (IVBT) stock price: $0.00 (+0.00, +0.00%)
Latest News
No recent news available for IVBT.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVBT.
Price Targets
Wall Street price target analysis for IVBT.
MoonshotScore
What does this score mean?
The MoonshotScore rates IVBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesIVBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Innovation1 Biotech Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in Innovation1 Biotech Inc.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- OTC Other stocks are subject to less regulatory oversight, increasing the risk of fraud or manipulation.
- The company's ability to continue operating is uncertain due to its status as a shell company on the OTC market.
- Potential delisting from the OTC market could further reduce liquidity and investor confidence.
- Verify the company's management team and their track record.
- Review any available financial statements and assess the company's financial health.
- Research the company's business model and competitive landscape.
- Assess the potential market for the company's products or services.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Confirm the company's legal standing and compliance with regulations.
- Focus on developing treatments for long covid, addressing a real market need.
- NLC001 drug in Phase II clinical trials suggests some level of scientific validation.
- Existing revenue stream from supplement sales provides some financial stability.
Innovation1 Biotech Inc. Stock: Key Questions Answered
What does Innovation1 Biotech Inc. do?
Innovation1 Biotech Inc. is a financial services company operating as a shell company focused on researching, developing, producing, and selling pharmaceutical products and supplements. The company's primary focus is on addressing the symptoms and treatment of flu and long covid. They market natural supplements under the NutraFlu and Nutravid19 brands, targeting symptom relief. Additionally, they are developing NLC001, a drug currently in Phase II clinical trials, aimed at treating long covid and other viral indications. The company's business model combines supplement sales with the potential for future revenue from pharmaceutical drug development.
What do analysts say about IVBT stock?
There is currently no available analyst coverage for Innovation1 Biotech Inc. (IVBT). Given the company's OTC listing and shell company status, it is less likely to be actively tracked by major financial analysts. Investors should conduct their own thorough due diligence and consider the risks associated with investing in a company with limited analyst coverage. Key valuation metrics are not readily available, and growth considerations are highly dependent on the successful development and commercialization of NLC001.
What are the main risks for IVBT?
Innovation1 Biotech Inc. faces several key risks. The primary risk is the potential failure of NLC001 in clinical trials or regulatory approval processes, which would significantly impact the company's future prospects. As an OTC-listed company, IVBT faces risks associated with limited liquidity, potential price volatility, and less stringent regulatory oversight. The company's high beta of 17.37 indicates significant volatility compared to the market. Additionally, competition from established pharmaceutical companies and the need for substantial capital investment in research and development pose ongoing challenges.
What are the key factors to evaluate for IVBT?
Innovation1 Biotech Inc. (IVBT) currently holds an AI score of 47/100, indicating low score. Key strength: Focus on emerging health needs (long covid).. Primary risk to monitor: Potential: Failure of NLC001 in clinical trials.. This is not financial advice.
How frequently does IVBT data refresh on this page?
IVBT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IVBT's recent stock price performance?
Recent price movement in Innovation1 Biotech Inc. (IVBT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on emerging health needs (long covid).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IVBT overvalued or undervalued right now?
Determining whether Innovation1 Biotech Inc. (IVBT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IVBT?
Before investing in Innovation1 Biotech Inc. (IVBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be readily available or reliable.